Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer

被引：33
作者：
Booka, Eisuke [1 ]
Kikuchi, Hirotoshi [1 ]
Haneda, Ryoma [1 ]
Soneda, Wataru [1 ]
Kawata, Sanshiro [1 ]
Murakami, Tomohiro [1 ]
Matsumoto, Tomohiro [1 ]
Hiramatsu, Yoshihiro [1 ,2 ]
Takeuchi, Hiroya [1 ]
机构：
[1] Hamamatsu Univ Sch Med, Dept Surg, Shizuoka, Japan
[2] Hamamatsu Univ Sch Med, Dept Perioperat Functioning Care & Support, Shizuoka, Japan
来源：
ANTICANCER RESEARCH | 2022年 / 42卷 / 06期
关键词：
Neutrophil-to-lymphocyte ratio; immune checkpoint inhibitor; esophageal squamous cell carcinoma; gastric; gastroesophageal adenocarcinoma; SQUAMOUS-CELL CARCINOMA; GASTROESOPHAGEAL JUNCTION; ESOPHAGEAL; NIVOLUMAB; BIOMARKER; IMPACT; BLOOD;
D O I：
10.21873/anticanres.15781
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: Although the effectiveness of immune checkpoint inhibitors (ICIs) in upper gastrointestinal (UGI) cancer including esophageal squamous cell carcinoma (ESCC) and gastric/gastroesophageal adenocarcinoma (GEA) has been proven, prediction of their efficacy remains unknown. This study aimed to develop optimal serum nutritional indicators or a combination of blood cell components to predict the efficacy of ICI before beginning UGI cancer treatment. Patients and Methods: We retrospectively reviewed the data of 61 UGI cancers (31 ESCC and 30 GEA) patients treated with nivolumab or pembrolizumab. We investigated the impact of serum albumin level, total lymphocyte count (TLC), prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-tomonocyte ratio (LMR) on the efficacy of ICIs and long-term survival. The median cutoff value was adopted separately in ESCC and GEA. Results: NLR-Low was significantly correlated with better overall survival (p=0.014), and PLR-Low was significantly correlated with improved disease control rate and better progression-free survival in UGI cancer patients. Both results indicate that a better prognosis is correlated to a greater number of lymphocytes. Multivariate analysis revealed that NLR-High [hazard ratio (HR)=2.865; 95% confidence interval (CI)=1.030-7.937; p=0.044] was the only independent poor
引用
收藏
页码：2977 / 2987
页数：11
相关论文
共 32 条
[1]  
[Anonymous], 2010, Common Terminology Criteria for Adverse Events (CTCAE)
[2]   Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) [J].
Boku, N. ;
Ryu, M. -H. ;
Kato, K. ;
Chung, H. C. ;
Minashi, K. ;
Lee, K. -W. ;
Cho, H. ;
Kang, W. K. ;
Komatsu, Y. ;
Tsuda, M. ;
Yamaguchi, K. ;
Hara, H. ;
Fumita, S. ;
Azuma, M. ;
Chen, L. -T. ;
Kang, Y. -K. .
ANNALS OF ONCOLOGY, 2019, 30 (02) :250-258
[3]   Impact of Immune-related Adverse Events on Nivolumab Efficacy in Patients With Upper Gastrointestinal Cancer [J].
Booka, Eisuke ;
Kikuchi, Hirotoshi ;
Haneda, Ryoma ;
Soneda, Wataru ;
Kawata, Sanshiro ;
Murakami, Tomohiro ;
Matsumoto, Tomohiro ;
Hiramatsu, Yoshihiro ;
Takeuchi, Hiroya .
IN VIVO, 2021, 35 (04) :2321-2326
[4]   Whole exome sequencing and deep sequencing of esophageal squamous cell carcinoma and adenocarcinoma in Japanese patients using the Japanese version of the Genome Atlas, JCGA [J].
Booka, Eisuke ;
Tsubosa, Yasuhiro ;
Yokota, Tomoya ;
Mayanagi, Shuhei ;
Ishii, Kenjiro ;
Urakami, Kenichi ;
Ohshima, Keiichi ;
Ohnami, Shumpei ;
Nagashima, Takeshi ;
Yamaguchi, Ken .
ESOPHAGUS, 2021, 18 (04) :743-752
[5]   Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment [J].
Chanmee, Theerawut ;
Ontong, Pawared ;
Konno, Kenjiro ;
Itano, Naoki .
CANCERS, 2014, 6 (03) :1670-1690
[6]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[7]   The immune contexture in human tumours: impact on clinical outcome [J].
Fridman, Wolf Herman ;
Pages, Franck ;
Sautes-Fridman, Catherine ;
Galon, Jerome .
NATURE REVIEWS CANCER, 2012, 12 (04) :298-306
[8]   Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue [J].
Grimm, Martin ;
Feyen, Oliver ;
Hofmann, Heiko ;
Teriete, Peter ;
Biegner, Thorsten ;
Munz, Adelheid ;
Reinert, Siegmar .
TUMOR BIOLOGY, 2016, 37 (03) :3807-3816
[9]   Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors [J].
Guo, Jhe-Cyuan ;
Lin, Chia-Chi ;
Lino, Chen-Yuan ;
Hsieh, Min-Shu ;
Ku, Hung-Yang ;
Lien, Ming-Yu ;
Shao, Yu-Yun ;
Huang, Ta-Chen ;
Hsu, Chih-Hung .
ANTICANCER RESEARCH, 2019, 39 (10) :5675-5682
[10]   Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma [J].
Han, Sheng ;
Liu, Yang ;
Li, Qingchang ;
Li, Zhonghua ;
Hou, Haipei ;
Wu, Anhua .
BMC CANCER, 2015, 15
1234